Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis.

Published on May 1, 2021in Neuroendocrinology4.271
· DOI :10.1159/000508376
Massimo Milione31
Estimated H-index: 31
Patrick Maisonneuve134
Estimated H-index: 134
+ 24 AuthorsCarlo Capella89
Estimated H-index: 89
BACKGROUND: Little information is available concerning prognostic factors of bronchopulmonary large cell neuroendocrine carcinomas (BP-LCNECs) and even less is known about combined LCNECs (Co-LCNECs). We investigated whether an integrated morphological, immunohistochemical and molecular approach could be used for their prognostic evaluation. METHODS: Morphological (including combined features), proliferative (mitotic count/Ki-67 index), immunohistochemical (napsin A, p-40, TTF-1, CD44, OTP, SSTR2A, SSTR5, mASH1, p53, RB1, MDM2) and genomic (TP53, RB1, ATM, JAK2, KRAS, STK11) findings were analyzed from BP-LCNECs from 5 Italian centers, and correlated with overall survival (OS). Ki-67 was expressed as a percentage of positive cells in hot spot as indicated in the WHO 2019 Digestive System Tumors and, for Co-LCNEC, Ki-67 was evaluated only in the LCNEC component. RESULTS: 111 LCNECs were distinguished in: 70 pure LCNECs, 35 co-LCNECs [27 with adenocarcinoma (ADC); 8 with squamous cell carcinoma (SqCC) and 6 LCNECs with only napsin A immunoreactivity]. Ki-67 cut off at 55% evaluated in the NE component was the most powerful OS predictor (Log-rank P=0.0001) in all LCNECs: 34 LCNECs-A Ki-67 /=55%; statistical differences in OS (Log-rank P=0.0001) were also observed between pure and co-LCNECs. A significant difference in OS was found between pure LCNEC-A and co-LCNEC-A (P<0.05) but not between pure LCNEC-B and Co-LCNEC-B. Co-LCNEC-ADC and LCNEC Napsin A+ cases had longer OS than pure LCNEC and Co-LCNEC-SqCC cases (Log-rank P=0.0001). At multivariable analysis, tumor location, pure vs combined features and napsin A, but no single gene mutation, were significantly associated with OS, after adjustment for Ki-67 and study center (P<0.05). CONCLUSIONS: The Ki-67 proliferation index and the morphologic characterization of combined features in LCNECs seem to be important tools for predicting clinical outcome in BP-LCNECs.
📖 Papers frequently viewed together
206 Citations
4 Citations
5 Citations
Cited By5
#1Stefano La Rosa (UNIL: University of Lausanne)H-Index: 38
#2Silvia Uccella (University of Insubria)H-Index: 25
Neuroendocrine neoplasms (NENs) are a heterogeneous group of neoplastic proliferations showing different morphological features, immunophenotype, molecular background, clinical presentation, and outcome. They can virtually originate in every organ of the human body and their classification is not uniform among different sites. Indeed, as they have historically been classified according to the organ in which they primarily arise, the different nomenclature that has resulted have created some conf...
4 CitationsSource
#1Anne Couvelard (University of Paris)H-Index: 69
#2Jérôme Cros (University of Paris)H-Index: 32
Last. Aurélie Cazes (University of Paris)H-Index: 27
view all 5 authors...
Abstract High grade neuroendocrine neoplasms (NENs) include poorly differentiated carcinomas (NECs) and well-differentiated tumours (NETs). NECs, especially LCNECs, can be difficult to distinguish from non-neuroendocrine carcinoma expressing neuroendocrine markers and from mixed NENs (called MiNENs in the digestive tract and combined carcinomas in the lung, with different criteria of definition). Recent studies on the genetic profiles of LCNECs showed that they are heterogeneous, some of them pr...
#1Manuela Albertelli (UniGe: University of Genoa)H-Index: 17
#2Federica Grillo (UniGe: University of Genoa)H-Index: 25
Last. Maria Chiara ZatelliH-Index: 51
view all 7 authors...
During the 5th NIKE (Neuroendocrine tumors Innovation in Knowledge and Education) meeting, held in Naples, Italy, in May 2019, discussions centered on the understanding of pathology reports of gastroenetropancreactic neuroendocrine neoplasms. In particular, the main problem concerned the difficulty that clinicians experience in extrapolating relevant information from neuroendocrine tumor pathology reports. During the meeting, participants were asked to identify and rate issues which they have en...
1 CitationsSource
Last. Junya Fukuoka (Nagasaki University)H-Index: 40
view all 4 authors...
Pulmonary large cell neuroendocrine carcinoma (LCNEC) is an aggressive neoplasm with poor prognosis. Histologic diagnosis of LCNEC is not always straightforward. In particular, it is challenging to distinguish small cell lung carcinoma (SCLC) or poorly differentiated carcinoma from LCNEC. However, histological classification for LCNEC as well as their therapeutic management has not changed much for decades. Recently, genomic and transcriptomic analyses have revealed different molecular subtypes ...
#1Giovanni CentonzeH-Index: 11
#2Davide BiganzoliH-Index: 1
Last. Massimo MilioneH-Index: 31
view all 14 authors...
Lung neuroendocrine neoplasms (LNENs) represent a rare and heterogeneous population of lung tumors. LNENs incidence rate has increased dramatically over the past 30 years. The current World Health Organization LNENs classification (WHO 2015), distinguished four LNENs prognostic categories, according to their morphology, necrosis amount and mitotic count: typical carcinoid (TC), atypical-carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC) and small cell lung cancer (SCLC). At present, due...
5 CitationsSource